Literature DB >> 7947427

Prolonged analgesia with liposomal bupivacaine in a mouse model.

G J Grant1, K Vermeulen, L Langerman, M Zakowski, H Turndorf.   

Abstract

BACKGROUND AND OBJECTIVES: Currently available local anesthetics have relatively limited duration of action and some may cause severe systemic toxicity. An ultralong lasting local anesthetic would be useful to produce prolonged intraoperative anesthesia and extended postoperative analgesia. The goal of this study was to synthesize a sustained release local anesthetic formulation that would produce prolonged sensory block and decrease the possibility of systemic toxicity.
METHODS: The effect of liposomes containing 1.1% bupivacaine on duration of sensory block of the mouse tail was compared with equivalent concentrations of bupivacaine with and without epinephrine. Analgesia was assessed using the tail flick test. Systemic toxicity (LD50) was assessed after intraperitoneal injection and in vitro release rates were compared by dialysis technique for liposomal and plain bupivacaine.
RESULTS: Sensory block was significantly prolonged with liposomal bupivacaine (130 +/- 38 minutes) compared to plain bupivacaine (46 +/- 11 minutes, P < .01) or bupivacaine with epinephrine (81 +/- 28 minutes, P < .05). The LD50 was significantly lower for plain bupivacaine (61 mg/kg, 95% confidence intervals 47-79) than for liposomal bupivacaine (291 mg/kg, 95% confidence intervals 201-422). The time to 50% in vitro release through a dialysis membrane for liposomal bupivacaine (28 +/- 9 minutes) was markedly prolonged compared to plain bupivacaine (7 +/- 1 minutes).
CONCLUSIONS: This study shows that liposomal encapsulation of bupivacaine significantly prolongs duration of action and greatly decreases systemic toxicity of the drug. These findings may be promising for the future production of formulations of ultralong lasting local anesthetics with enhanced efficacy and safety.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947427

Source DB:  PubMed          Journal:  Reg Anesth        ISSN: 0146-521X


  8 in total

1.  DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice.

Authors:  G J Grant; Y Barenholz; B Piskoun; M Bansinath; H Turndorf; E M Bolotin
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Multivesicular liposomal bupivacaine at the sciatic nerve.

Authors:  J Brian McAlvin; Robert F Padera; Sahadev A Shankarappa; Gally Reznor; Albert H Kwon; Homer H Chiang; Jason Yang; Daniel S Kohane
Journal:  Biomaterials       Date:  2014-03-06       Impact factor: 12.479

3.  Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine.

Authors:  D S Kohane; M Lipp; R C Kinney; N Lotan; R Langer
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

4.  Local myotoxicity from sustained release of bupivacaine from microparticles.

Authors:  Robert Padera; Evangelia Bellas; Julie Y Tse; Daphne Hao; Daniel S Kohane
Journal:  Anesthesiology       Date:  2008-05       Impact factor: 7.892

Review 5.  Vanilloid-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low level of potential neurotoxicity.

Authors:  Igor Kissin
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

6.  Local toxicity from local anesthetic polymeric microparticles.

Authors:  J Brian McAlvin; Gally Reznor; Sahadev A Shankarappa; Cristina F Stefanescu; Daniel S Kohane
Journal:  Anesth Analg       Date:  2013-03-04       Impact factor: 5.108

7.  Clinical Management of Pain in Rodents.

Authors:  Patricia L Foley; Lon V Kendall; Patricia V Turner
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

Review 8.  Mouse Anesthesia: The Art and Science.

Authors:  Kaela L Navarro; Monika Huss; Jennifer C Smith; Patrick Sharp; James O Marx; Cholawat Pacharinsak
Journal:  ILAR J       Date:  2021-12-31       Impact factor: 1.521

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.